Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shuli Qu

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Journal of Public Health Management and Practice : JPHMP|July 24, 2015
High School Completion Programs: A Community Guide Systematic Economic ReviewShuli Qu, Sajal K Chattopadhyay, Robert A Hahn, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|September 25, 2020
Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in chinaJiujie Cui, Xiaochen Zhang, Shuli Qu, et al.
Current Medical Research and Opinion|August 31, 2019
Lixisenatide versus insulin glulisine on top of insulin glargine in patients with type 2 diabetes mellitus: a cost-per-responder analysis in ChinaPeng Men, Chaoyun Li, Suodi Zhai, et al.
Journal of Comparative Effectiveness Research|September 4, 2019
Comparative clinical effects and cost-effectiveness of maximum androgen blockade, docetaxel with androgen deprivation therapy and ADT alone for the treatment of mHSPC in ChinaMaobai Liu, Shuli Qu, Yanjun Liu, et al.
Diabetes, Obesity & Metabolism|August 31, 2019
Comparison of lixisenatide in combination with basal insulin vs other insulin regimens for the treatment of patients with type 2 diabetes inadequately controlled by basal insulin: Systematic review, network meta-analysis and cost-effectiveness analysisPeng Men, Shuli Qu, Wenting Luo, et al.
Annals of Translational Medicine|May 16, 2022
Cost-effectiveness analysis of vonoprazan versus proton pump inhibitors in the treatment of reflux esophagitis in ChinaZhenhua Wang, Ruixiaotong Sun, Yanan Sheng, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 21, 2020
Lixisenatide for Type 2 Diabetes Mellitus Patients Inadequately Controlled on Oral Antidiabetic Drugs: A Mixed-Treatment Comparison Meta-analysis and Cost-Utility AnalysisPeng Men, Shuli Qu, Zhenqiang Song, et al.
Clinical Drug Investigation|November 28, 2019
A Caprini Risk Score-Based Cost-Effectiveness Analysis of Enoxaparin for the Thromboprophylaxis of Patients After Nonorthopedic Surgery in a Chinese Healthcare SettingYun Bao, Gang Zhao, Shuli Qu, et al.
Cost Effectiveness and Resource Allocation : C/E|December 25, 2019
Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysisXin Hu, Shuli Qu, Xingxing Yao, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|April 16, 2020
Comparative cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in ChinaZhan-Miao Yi, Peng Men, Shuli Qu, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Journal of Public Health Management and Practice : JPHMP|July 24, 2015
High School Completion Programs: A Community Guide Systematic Economic ReviewShuli Qu, Sajal K Chattopadhyay, Robert A Hahn, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|September 25, 2020
Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in chinaJiujie Cui, Xiaochen Zhang, Shuli Qu, et al.
Current Medical Research and Opinion|August 31, 2019
Lixisenatide versus insulin glulisine on top of insulin glargine in patients with type 2 diabetes mellitus: a cost-per-responder analysis in ChinaPeng Men, Chaoyun Li, Suodi Zhai, et al.
Journal of Comparative Effectiveness Research|September 4, 2019
Comparative clinical effects and cost-effectiveness of maximum androgen blockade, docetaxel with androgen deprivation therapy and ADT alone for the treatment of mHSPC in ChinaMaobai Liu, Shuli Qu, Yanjun Liu, et al.
Diabetes, Obesity & Metabolism|August 31, 2019
Comparison of lixisenatide in combination with basal insulin vs other insulin regimens for the treatment of patients with type 2 diabetes inadequately controlled by basal insulin: Systematic review, network meta-analysis and cost-effectiveness analysisPeng Men, Shuli Qu, Wenting Luo, et al.
Annals of Translational Medicine|May 16, 2022
Cost-effectiveness analysis of vonoprazan versus proton pump inhibitors in the treatment of reflux esophagitis in ChinaZhenhua Wang, Ruixiaotong Sun, Yanan Sheng, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 21, 2020
Lixisenatide for Type 2 Diabetes Mellitus Patients Inadequately Controlled on Oral Antidiabetic Drugs: A Mixed-Treatment Comparison Meta-analysis and Cost-Utility AnalysisPeng Men, Shuli Qu, Zhenqiang Song, et al.
Clinical Drug Investigation|November 28, 2019
A Caprini Risk Score-Based Cost-Effectiveness Analysis of Enoxaparin for the Thromboprophylaxis of Patients After Nonorthopedic Surgery in a Chinese Healthcare SettingYun Bao, Gang Zhao, Shuli Qu, et al.
Cost Effectiveness and Resource Allocation : C/E|December 25, 2019
Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysisXin Hu, Shuli Qu, Xingxing Yao, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|April 16, 2020
Comparative cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in ChinaZhan-Miao Yi, Peng Men, Shuli Qu, et al.
Pageof 3